Decoy Therapeutics Files Prospectus Related To The Resale Of Up To 2,368,868 Common Shares
-SEC Filing
Stocks · News reference
Decoy Therapeutics Provides Third Quarter 2026 Business Update
Decoy Therapeutics reported progress on its antiviral pipeline, highlighting an optimized pan-coronavirus lead candidate and a cash position of $8.1 million.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Decoy Therapeutics Says Preclinical Data Show Single Intranasal Dose Of DCOY-CoV Maintains Drug Levels For Up To 7 Days; Expects Clinical Trials In 2027
8-K filing — Decoy Therapeutics Inc. (DCOY)
Filed: 2026-09-23 AccNo: 0001615219-26-000019 Size: 593 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results
U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.
Decoy Therapeutics To Exercise 1,184,434 Series B Warrants At $3.25/Share for ~$3.85M; Cuts Series A & C Warrant Prices To $3.25 And Issues 2,368,868 New Warrants At $3.25/Share
Decoy Therapeutics, Inc. (NASDAQ:DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral